| 单词 | Remicade |
| 例句 | It was set up by Jan T. Vilcek, a scientist at New York University who made a fortune for research that led to the drug Remicade, an important anti-inflammatory. ArtsBeat: A $100,000 Prize for Yo-Yo Ma 2013-02-04T21:17:59Z Earlier in the day, he’d been treated with Remicade, which is administered through an IV drip. Pete Davidson Nuzzles Up to the Prickly Joke 2015-10-01T04:00:00Z Instead, it would focus on high-dollar, specialty intravenous medications like Remicade, which is used for arthritis and other autoimmune conditions. Decisions by CVS and Optum panicked thousands of their sickest patients 2023-02-12T05:00:00Z Instead, it would focus on high-dollar, specialty intravenous medications such as Remicade, which is used for arthritis and other autoimmune conditions. Patients needing home IV nutrition fear dangerous shortages 2023-02-06T05:00:00Z The two drugs he takes, Entyvio and Remicade, have the same purpose — to reduce inflammation in the large intestine — but each works differently in the body. “We’re still gonna say no”: UnitedHealthcare’s effort to deny coverage to chronically ill patient 2023-02-02T05:00:00Z They found that less than half of patients who took Remicade mounted an immune response following coronavirus infection. Vaccines Won’t Protect Millions of Patients With Weakened Immune Systems 2021-04-15T04:00:00Z Resuming coverage of Remicade, as the court ordered, did not reverse Pfizer’s gains. J&J's Remicade losing ground in Quebec health plan despite court victory 2019-11-13T05:00:00Z Remicade, an older immune disorder blockbuster that is facing increased competition, saw revenue drop 16 % to $1.11 billion. Johnson & Johnson 2Q profit jumps 42% despite lower sales 2019-07-16T04:00:00Z The company entered in the U.S. market in July 2017 with a highly similar version of Johnson & Johnson ’s blockbuster rheumatoid-arthritis drug Remicade. Samsung Faces Resistance From Big Pharma in the U.S. 2019-01-11T05:00:00Z Remicade, marketed by Janssen Biotech, targets a protein that causes inflammation. “We’re still gonna say no”: UnitedHealthcare’s effort to deny coverage to chronically ill patient 2023-02-02T05:00:00Z The maker of baby products, medical devices and blockbuster immune disorder drug Remicade on Tuesday reported revenue of $20.01 billion, topping analyst projections for $19.48 billion. Johnson & Johnson tops 1Q views on sales spike, but net dips 2018-04-17T04:00:00Z Johnson & Johnson’s patent on its top-selling arthritis drug Remicade is invalid, a U.S. appeals court ruled Tuesday in a defeat to the drugmaker that just last week lost a patent on another blockbuster medicine. New York City sues opioid companies, blaming them for epidemic 2018-01-23T05:00:00Z However, revenue from J&J;’s top-selling medicine, Remicade for rheumatoid arthritis, Crohn’s disease and other immune conditions, fell nearly 10 percent due to increasing competition from biosimilars. Johnson & Johnson loses $10.7B after sweeping US tax changes 2018-01-23T05:00:00Z Every eight weeks, she takes the two with Crohn’s to a hospital for infusions of Remicade, an expensive biologic drug. With Children’s Health Program Running Dry, Parents Beg Congress: ‘Do the Right Thing’ 2017-12-19T05:00:00Z Sales of some older drugs declined amid increased competition from other brand-name drugs or generics, particularly top seller Remicade for rheumatoid arthritis and other immune disorders. Johnson & Johnson tops Street 3Q forecasts, hikes forecast 2017-10-17T04:00:00Z Top seller Remicade, for rheumatoid arthritis, ulcerative colitis and other immune disorders, saw sales fall 17 percent to $1.39 billion, hurt by recent competition in the U.S. Johnson & Johnson tops 1Q views on sales spike, but net dips 2018-04-17T04:00:00Z “Competition is bringing down the overall cost of Remicade, and will continue to bring down costs in the future.” Pfizer sues Johnson & Johnson, alleging anticompetitive practices to maintain a drug monopoly 2017-09-20T04:00:00Z Pfizer launched its own version of Remicade, Inflectra, last year and sells it at a 19 percent discount on J&J’s list price. Chipotle stock down over norovirus reports 2017-07-24T04:00:00Z The new drug is the second non-branded version of Johnson & Johnson’s blockbuster drug Remicade to hit the U.S. market. How Blockbuster Drugs Fight Off Cheaper Competition 2017-07-24T04:00:00Z A unit of healthcare conglomerate Johnson & Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States. Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy 2017-05-18T04:00:00Z He currently gets Remicade infusions every six weeks and coupled with the diet, he’s able to manage the disease. Beamer freshman Nate Clowe: ‘It’s not really worth hiding’ from his disease, ulcerative colitis 2017-05-07T04:00:00Z Federal regulators on Friday approved another alternative version of Remicade, an expensive injected drug widely used for rheumatoid arthritis and other immune system disorders. FDA approves 2nd near-copy of Remicade for immune disorders 2017-04-21T04:00:00Z The company’s revenue was weaker than expected as sales of its Crohn’s disease drug Remicade declined 6 percent. Sharp losses for banks, health care stocks pull indexes down 2017-04-18T04:00:00Z The sales miss was also driven by generic competition for its cholesterol treatment, Zetia, and biosimilar competition for its autoimmune treatment, Remicade, in Europe. Merck 2017 forecast eases concerns over royalty payments, dollar 2017-02-02T05:00:00Z Remicade is Johnson & Johnson's biggest selling drug, with U.S. sales of about $5 billion a year. Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy 2017-05-18T04:00:00Z A side effect of the Remicade is lymphoma. Beamer freshman Nate Clowe: ‘It’s not really worth hiding’ from his disease, ulcerative colitis 2017-05-07T04:00:00Z J&J's biggest product, the arthritis drug Remicade, faces cheaper competition from Pfizer Inc. J&J Ends Takeover Talks With Actelion 2016-12-13T05:00:00Z It remains to be seen whether new competition will actually put a damper on Remicade sales, but the stakes are high. Costly Biotech Bet Still Worth It for J&J 2016-11-28T05:00:00Z Sales of Remicade, a treatment for inflammatory diseases, dropped 30% due to the impact of competition by biosimilar drugs in Europe. Merck Revenue and Profit Rise on Cancer Drugs, Vaccines 2016-10-25T04:00:00Z District Court of New Jersey dated Wednesday, seeks a preliminary or permanent injunction to block Samsung Bioepis' biosimilar of Remicade from sale and argues the South Korean firm violated three of its patents. Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy 2017-05-18T04:00:00Z Remicade is approved for treatment of rheumatoid arthritis, psoriasis, colitis and other immune system disorders. Health Highlights: Oct. 18, 2016 2016-10-18T04:00:00Z However, the company is set to face competition for Remicade in the United States. J&J revenue, profit edge past estimates on robust drug sales 2016-10-18T04:00:00Z Remicade sales accounted for more than a third of third-quarter pharmaceuticals revenue. Costly Biotech Bet Still Worth It for J&J 2016-11-28T05:00:00Z Remicade, long J&J;’s top-selling drug, is approved for treating rheumatoid arthritis, psoriasis, colitis and other immune system disorders. Pfizer to launch cheaper version of J&J immune drug Remicade 2016-10-17T04:00:00Z J&J, in an emailed statement, said it considers any sales by Pfizer of a Remicade biosimilar to be an "at risk launch." Pfizer set to start shipping Remicade biosimilar next month 2016-10-17T04:00:00Z A cheaper version of Johnson & Johnson's immune disorder drug Remicade will soon be available. Health Highlights: Oct. 18, 2016 2016-10-18T04:00:00Z Remicade, long J&J's top-selling drug, is approved for treating rheumatoid arthritis, psoriasis, colitis and other immune system disorders. Pfizer to launch cheaper version of J&J immune drug Remicade 2016-10-17T04:00:00Z Remicade and Enbrel, two of the world’s top-selling drugs because of their steep prices, treat rheumatoid arthritis, psoriasis, colitis and other immune system disorders. Insider Q&A: Why so little relief on pricey biologic drugs 2016-09-18T04:00:00Z J&J; said in a statement it will compete with Inflectra “through a variety of innovative contracting options, discounts and rebates to payers, providers and pharmacy benefit managers” to keep Remicade affordable for patients. Pfizer to launch cheaper version of J&J immune drug Remicade 2016-10-17T04:00:00Z Remicade is J&J's biggest selling drug with U.S. sales of about $5 billion a year. Pfizer set to start shipping Remicade biosimilar next month 2016-10-17T04:00:00Z Remicade is approved for treating chronic conditions in which the immune system goes haywire and attacks part of the body, including rheumatoid arthritis, ulcerative colitis, psoriasis and Crohn's disease. Patent for J&J's Remicade Invalidated, Cheaper Version Looms 2016-08-17T04:00:00Z Remicade, first approved for sale in the U.S. in 1998, is J&J’s largest product by sales, accounting for $6.56 billion in sales last year, including $4.5 billion in the U.S. Court Says Pfizer’s Biosimilar of J&J’s Remicade Doesn’t Infringe Patent 2016-08-17T04:00:00Z Pfizer won approval to market a second biosimilar in April, a version of Johnson & Johnson's Remicade, but it is not yet for sale. Lower-cost biotech drug gets thumbs up from FDA panel 2016-07-12T04:00:00Z Older biologics include brands like Enbrel and Remicade, which target an immune system chemical called TNF. New Psoriasis Drug Works Longer Term, Too 2016-06-08T04:00:00Z J&J said it expects to be competitive with the Remicade biosimilar. Pfizer set to start shipping Remicade biosimilar next month 2016-10-17T04:00:00Z Remicade is an injected biologic drug, "manufactured" in living cells rather than by mixing chemicals. Patent for J&J's Remicade Invalidated, Cheaper Version Looms 2016-08-17T04:00:00Z U.S. regulators earlier this month approved a rival version of the company's Remicade treatment for conditions such as rheumatoid arthritis. Investors find safety in J&J shares, but run could stall 2016-04-14T04:00:00Z SmartShopper’s Graybill said one woman switched her monthly infusion of Remicade, a medicine for Crohn’s disease and rheumatoid arthritis, from a hospital to an infusion center. Shopping for Health Care: A Fledgling Craft 1463-11-23T05:00:00Z Remicade was the first TNF-blocking agent approved by the US Food and Drug Administration, initially for treating Crohn's disease, in 1998. Drug discovery: A life of tumult and triumph : Nature : Nature Publishing Group 2016-02-09T05:00:00Z In addition to rheumatoid arthritis Inflectra, like Remicade, is also approved to treat Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis and the spine condition ankylosing spondylitits. Pfizer set to start shipping Remicade biosimilar next month 2016-10-17T04:00:00Z The FDA released the documents a week ahead of Celltrion Inc.’s panel meeting suggesting the Korean pharmaceutical’s proposed biosimilar of Johnson & Johnson’s Remicade is close... J&J, AbbVie Shares Drop on Potential Drug Competition 2016-02-05T05:00:00Z The company said sales of its diabetes drug, Januvia, fell 12 percent to $1.45 billion in the fourth quarter, while sales of its arthritis drug, Remicade, fell 29 percent to $396 million. Merck's Revenue Misses on Lower Drug Sales, Strong Dollar 2016-02-03T05:00:00Z The European Commission said Pfizer agreed to sell the European rights to the experimental biosimilar version of the immune-disorder drug Remicade and a few other products, including some chemotherapy drugs, in certain markets. Appeals court revives ATM-fee lawsuit 2015-08-04T04:00:00Z Remicade was one of the earliest of a complex category of biotechnology drugs when it was introduced in 1998, and is now approved to treat a range of conditions including rheumatoid arthritis and gastrointestinal disorders. Merck Earnings Hurt by Arthritis Drug Knockoffs 2015-07-28T04:00:00Z Second, J&J’s key drugs Zytiga and Remicade are facing more competition than ever. We Expect The Stability In J&J's Stock To Continue 2015-07-16T04:00:00Z It also is preparing for the threat of increased competition in the U.S. from lower priced biosimilar versions of its blockbuster anti-inflammatory drug Remicade. J&J Fights Off Stronger Dollar, Competition 2015-07-14T04:00:00Z With Remicade going off patent and Olysio’s sales plummeting, J&J needs new catalysts to drive its growth. Investors Are Likely To Focus On 'What's New' During Johnson & Johnson's Second Quarter Earnings 2015-07-10T04:00:00Z Remicade accounts for roughly 25% of J&J’s pharmaceutical revenues and therefore, a significant propotion of the company’s business is at risk. Growth Will Suffer As J&J Reports Its First Quarter Results 2015-04-10T04:00:00Z Merck officials said Tuesday the company has had success convincing European health systems and doctors to keep existing Remicade patients on the drug. Merck Earnings Hurt by Arthritis Drug Knockoffs 2015-07-28T04:00:00Z We previously stated that with Remicade going off patent and Olysio’s sales plummeting, J&J needs new catalysts to drive growth. We Expect The Stability In J&J's Stock To Continue 2015-07-16T04:00:00Z Remicade accounts for roughly 25% of J&J’s pharmaceutical revenues and there is no doubt that this percentage will decline meaningfully this year. Johnson & Johnson's EPS Will Rise, But Here Are The Risks 2015-03-27T04:00:00Z Remicade is used to treat rheumatoid arthritis and psoriasis. FDA OK of 1st 'Biosimilar' Drug May Mean Cheaper Options for Patients 2015-03-06T05:00:00Z An agency advisory committee was scheduled to meet this month to consider a biosimilar version of Johnson & Johnson’s Remicade but the meeting was postponed. F.D.A. Approves Zarxio, Its First Biosimilar Drug 2015-03-06T05:00:00Z Morgan analyst Chris Schott said he expects sales erosion for Remicade to accelerate in Europe throughout the rest of the year. Merck Earnings Hurt by Arthritis Drug Knockoffs 2015-07-28T04:00:00Z There are some existing drugs that are doing well but the competition is increasing and Remicade, J&J’s biggest drug, is losing its patent protection. Johnson & Johnson: Fourth Quarter Earnings And The Year Ahead 2015-01-15T05:00:00Z Johnson & Johnson, based in New Brunswick, New Jersey, is a leader in treatments for inflammatory bowel and other immune disorders, selling Remicade, Simponi and Stelara. Johnson & Johnson licenses Vedanta’s bowel disease drug 2015-01-13T05:00:00Z Drugs like Remicade and Humira are preferable and are normally covered by insurance, Lichtenstein said. Del. law opens employee bathrooms to those with medical need 2015-01-12T05:00:00Z A second biosimilar awaiting FDA review — an imitator of Johnson & Johnson and Merck’s rheumatoid arthritis drug, Remicade — would mean $17 billion in savings over the next decade, according to Express Scripts. A class of expensive drugs is getting cheaper competition for the first time 2015-01-07T05:00:00Z While we expect a continued decline in legacy products, revenues from its diabetes, drugs as well as anti-infective medicines and Remicade, will continue to grow. Merck Earnings Preview: Expect Continued Pressure On Topline Growth 2014-10-24T04:00:00Z While the expected competition for Olyiso is a cause of concern, there is another drug Remicade which is expected to lose patent protection in Europe in 2015. Johnson & Johnson Earnings Preview: Pharma Is Where The Party Is 2014-10-10T04:00:00Z While the expected competition for Olyiso is a cause of concern, there is another drug Remicade which is expected to lose patent in Europe in 2015. Johnson & Johnson Earnings: New Blockbuster Drug Olysio Lifts Sales But May Face Competition Soon 2014-07-16T04:00:00Z Remicade is an immunology drug and the biggest product for J&J’s pharmaceutical segment. Johnson & Johnson Earnings Should Show Pharma Buisness To Remain Strong 2014-07-11T04:00:00Z Sales jumped 10 percent to $604 million for immune disorder drug Remicade, and also rose for HIV drug Isentress and several other products. Merck First Quarter Profit Up Despite Sales Decline 2014-04-29T12:05:50Z Sales jumped 10 percent to $604 million for immune disorder drug Remicade, and sales also climbed for HIV drug Isentress and several other products. Merck First Quarter Profit Up Despite Sales Decline 2014-04-29T11:26:43Z Before taking that drug, Remicade, Dr. Kivi was on high doses of steroids for debilitating joint pain that left him unable to walk at times. Even Small Medical Advances Can Mean Big Jumps in Bills 2014-04-05T20:27:21Z From my inventor’s share of Remicade, I gave a percentage of future royalties to the foundation. A Conversation With Jan Vilcek: Defecting to Great Scientific Success 2013-07-22T19:19:42Z Royalty, which buys royalty rights on patented drugs, is keen to add lucrative revenues from Tysabri to its stable of streams that includes rheumatoid arthritis drugs Humira and Remicade. Elan rejects Royalty's $6.4 billion raised offer 2013-05-23T17:36:20Z Johnson & Johnson’s Remicade, a competing treatment that works in a similar way to Humira, must be given intravenously in the hospital. Humira From Abbott Supported for Ulcerative Colitis 2012-08-29T01:02:08Z Vedolizumab, which is given intravenously, belongs to a different class of biologic drugs than the TNF blockers widely used to treat colitis and other inflammatory diseases, such as Johnson & Johnson's Remicade and Abbott Laboratories' Humira. Takeda drug impresses in ulcerative colitis study 2012-05-22T15:51:57Z The average price that hospitals paid for Dr. Kivi’s dose of Remicade late last year was about $1,200, according to Medicare data. Even Small Medical Advances Can Mean Big Jumps in Bills 2014-04-05T20:27:21Z Three family members combined use about $13,000 worth of the drug Remicade, which is used to treat both conditions, each month. States Seek to Curb Exorbitant Drug Costs Incurred by Patients 2012-04-12T21:23:29Z Those gains were countered by a 16 percent decline in sales for the cholesterol drug Vytorin and a 28 percent drop for the arthritis drug Remicade. Merck Profit Beats Analyst Estimates on Diabetes Drug Sales 2012-02-02T13:56:25Z However, Remicade’s efficacy can diminish over time, forcing patients to switch to other therapies. A Graphic Use Of Drugs: How One Patient Visualized His Health Data 2011-11-29T20:01:55Z Within a week, doctors diagnosed him with Crohn’s and got Lerner on steady doses of Remicade. Florida P David Lerner wins starting job, earns scholarship while battling Crohn?s disease 2011-09-01T22:07:28Z The patent for Remicade also is expected to expire in the next few years. Abbott, others face generic competition 2011-05-24T23:49:58Z The drugmaker settled its dispute with New Brunswick, New Jersey based J&J in April over the arthritis drug Remicade, ending a conflict that weighed on Merck shares. Merck Profit Tops Analyst Estimates on Higher Drug Sales 2011-04-29T11:19:07Z The second-biggest U.S. drugmaker retained limited rights to a share of revenue from the arthritis drug Remicade after a settlement ended its dispute with partner Johnson & Johnson. U.S. Stocks Gain After Manufacturing, Confidence Reports Improve 2011-04-15T15:29:01Z The quality of life between Remicade and surgery is big, but all the options were not laid out for me,” he says. A Graphic Use Of Drugs: How One Patient Visualized His Health Data 2011-11-29T20:01:55Z Johnson & Johnson markets the rival treatments Simponi and Remicade, which are also injectable biotech drugs used to treat the conditions. Patent Ruling Is Reversed in Favor of Abbott Laboratories 2011-02-23T21:50:00Z J&J’s Remicade is made with a combination of mouse and human antibodies. Abbott Wins Reversal of J&J’s $1.67 Billion Patent Victory 2011-02-23T17:49:07Z J&J sells the competing medicine Remicade, made with a combination of mouse and human antibodies. Abbott Wins Bid to Reverse J&J $1.67 Billion Patent Win 2011-02-23T16:41:08Z These and other disappointments underscore the importance of the Remicade arbitration ruling. Analysis: Wisdom of Merck deal may hinge on Remicade ruling 2011-02-10T20:37:51Z Merck’s forecasts released today anticipate keeping the company’s full share of rights to Remicade. Merck 2011 Forecast Misses; Posts Net Loss on Drug 2011-02-03T12:47:04Z The dispute centers on rights to more than $2 billion in annual sales for two medicines for rheumatoid arthritis and other immune diseases, Remicade and successor drug Simponi. Panel hearings over Merck's dispute with J&J end 2010-10-14T20:31:00Z Remicade is J&J’s largest drug product, accounting for about 7.5 percent of the company’s business, or $4.61 billion in global sales. Abbott Wins Reversal of J&J’s $1.67 Billion Patent Victory 2011-02-23T17:49:07Z I think this is more of a Simponi story than Remicade. Analysis: Billions at stake in Merck/J&J Remicade dispute 2010-09-29T19:20:00Z Last fall, through her participation in a research study, Ms. Risco, 38, was prescribed Remicade, a drug typically given to patients with other autoimmune conditions. The New Landscape: Appealing Denied Health Claims May Not Be Easier Under New Law 2010-06-21T20:48:00Z Ms. Risco discontinued Remicade and started taking a different immune-suppressant drug that, while less effective, was approved by her health plan. The New Landscape: Appealing Denied Health Claims May Not Be Easier Under New Law 2010-06-21T20:48:00Z |
| 随便看 |
英语例句辞典收录了117811条英语例句在线翻译词条，基本涵盖了全部常用单词及词组的例句翻译及用法，是英语学习的有利工具。